FDA Updates COVID Vaccine Labels Amidst Myocarditis Concerns

FDA's Updated Vaccine Labeling

• ⚠️ The FDA has updated warning labels for COVID-19 mRNA vaccines to acknowledge the risks of myocarditis and pericarditis.
• 🎯 This update specifically addresses concerns regarding these heart conditions, particularly in young men.

Documented Risks and Data Suppression

• 📈 Studies indicate rates of vaccine-associated heart inflammation as high as 1 in 2,000 in males aged 18-24.
• 🤫 Critics argue that this data was known but suppressed by health agencies, including signals coming from the military.
• 🚫 Despite documented risks, the vaccines remain on the market, prompting calls for stronger warnings or removal.

Specific Risk Data

• 📊 A 2021 FDA regulatory action documented rates of postvaccination myocarditis from the Pfizer-BioNTech vaccine approaching 200 cases per million, or approximately 1 in 5,000, in young men.
• 🇭🇰 A prospective study in Hong Kong showed postvaccination myocarditis at approximately 1 in 3,000 for the second Pfizer dose in 13-18 year old men.
• 🔬 Analysis using Vaccine Safety Data Link (VSD) data suggested a 1 in 2,000 risk of post-second mRNA dose in 18-24 year old men.
• ⚠️ A study by Nicholas Holster from the McCulla Institute proved a causal link between COVID-19 vaccines and death from myocarditis, yet the FDA has not issued a class-one recall or a black-box warning.

Ongoing Concerns and Future Outlook

• 📉 The discussion highlights frustration over lingering mandates and concerns about vaccine effectiveness, with evidence suggesting increased COVID-19 risk with more doses.
• 🗣️ The FDA's Safety Labeling Change (SLC) is seen as a step in the right direction, but not sufficient, as the vaccines are still on the market and can cause permanent heart damage.
• ✅ There is a sentiment that regulatory agencies are beginning to move in the right direction, potentially rebuilding trust, with shared decision-making now recommended for pregnant women and children.